Shire CEO: Mydayis To Be Big ADHD Drug, But No Ex-US Launch Planned (Yet)

Flemming Ornskov says FDA approval of long-lasting ADHD therapy Mydayis is part of Shire's plan to dramatically increase neuroscience revenues – but it won't launch the drug outside the US for some time.